Clinical Trial: Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06241105) titled 'Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer' on Jan. 9.

Brief Summary: The investigators propose to initiate a study assessing the efficacy and safety of a lower initial dosage of lenvatinib combined with toripalimab in patients suffering from platinum-resistant recurrent ovarian cancer. The objective of this research is to offer a novel therapeutic approach for patients battling relapsed ovarian cancer with platinum resistance.

Study Type: Interventional

Condition: Recurrent Ovarian Carcinoma

Intervention: Drug: Lenvatinib+Toripalimab.

Adjustment of Medication Dosage: Throughout the course of trea...